Xspray Pharma
Xspray Pharma’s Nomination Committee for the Annual General Meeting 2023 (MFN)
Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) publishes the Nomination Committee’s composition for the Annual General Meeting in 2023.
The Nomination Committee, which has been appointed in accordance with the principles adopted by the Annual General Meeting on 19 May 2022, consists of:
- Thomas Eldered, appointed by Flerie Invest AB
- Johan Gyllenswärd, appointed by Ribbskottet AB
- Gillis Cullin, appointed by Östersjöstiftelsen
- Jan Särlvik, appointed by AP4
- Anders Ekblom, Chairman of the Board of Directors, Xspray Pharma AB
The Nomination Committee shall, before the Annual General Meeting 2023, prepare proposals for the election of Chairman and other members of the Board of Directors, the election of Chairman of the Annual Meeting, election of auditors, the determination of fees and matters pertaining thereto.
Shareholders who wish to submit proposals to the Nomination Committee prior to the Annual General Meeting on May 16, 2023, can do so via e-mail to generalmeeting@xspray.com before March 28, 2023.
For further information about the Nomination Committee, please contact:
Anders Ekblom, Chairman of the Board of Directors, Xspray Pharma AB
Email: anders.ekblom@xspray.com
For further information, please contact:
Christina Malmberg Hägerstrand
Senior Vice President Communications & Investor Relations
Xspray Pharma AB
Mob: +46 (0) 72 855 93 29
E-mail: christina.malmberg.hagerstrand@xspray.com
About Xspray Pharma
Xspray Pharma AB (publ) is a pharmaceutical company with several product candidates in clinical development. Xspray Pharma uses its innovative, patented RightSize™ technology to develop improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The segment is the second largest in oncology, and drug prices are very high.
The company´s innovative technology allows Xspray Pharma to gain entry as the first competitor to today’s original drugs before the secondary patents expire. Xspray’s goal is to become the leader in the development of improved drugs of PKIs already marketed for the treatment of cancer, which numbered to 72 in the end of 2021.
The company has patented manufacturing technology, equipment, and the resulting products. The shares in Xspray Pharma are traded on Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY).
www.xspraypharma.com